Bacilligen: Building on bacteria
Bacilligen Inc.. has three bacteria-based technology platforms that it believes confer safety, efficacy and manufacturing advantages when developing vaccines and therapeutics for infectious diseases and cancer, as well as allowing rapid manufacturing of therapeutic proteins and vaccines for emergency preparedness and personalized medicine.
The company's most advanced program is a next generation recombinant version of Bacillus Calmette-Guerin (BCG), an inactivated form of Mycobacterium tuberculosis, which is used in the developing world as a tuberculosis vaccine and in the U.S. to treat superficial bladder cancer. While effective in some cancer patients, BCG elicits a widespread immune reaction that makes it difficult for some patients to finish therapy. ...